Investors considering a purchase of Harrow Inc (Symbol: HROW) stock, but tentative about paying the going market price of $35.48/share, might benefit from considering selling puts among the ...
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the first quarter ended March 31, ...
Harrow, Inc. is an ophthalmology company with strong revenue growth, ambitious targets, and a diverse product portfolio including Vevye and Iheezo. HROW targets $280M in 2025 revenue and >$250M per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results